Published in Drug Law Weekly, June 13th, 2006
This patent is the first issued by the USPTO that claims certain of CCT's proprietary methodologies for recovering a variety of placental-derived stem cells (PDSCs) from a human placenta following birth. PDSCs appear to be highly versatile and may have the potential to repair and regenerate a broad range of damaged or diseased tissues. CCT scientists have successfully differentiated PDSCs into a variety of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.